Cancer Clinical Trial
Official title:
MODERATE CONTINUOUS TRAINING VERSUS HIIT ON CARDIOMETABOLIC AND PSYCHOSOCIAL VARIABLES IN CANCER STADIUM II.CONTROLLED RANDOMIZED TRIAL
Verified date | April 2019 |
Source | University Tolteca |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
Introduction: Exercise programs focused on moderate intensity continuous training (MICT) and
HIIT (High Intensity Interval Training) are shown as an effective treatment to mitigate the
effects of cancer.
Objective: To determine and compare the effects of MICT vs. HIIT on the cardiometabolic and
psychosocial variables of the cancer patient.
Methods and materials: Randomized controlled trial of 3 years and 4 months in participants
with stage II cancer divided into 3 groups (MICT, HIIT and control group). Risk factors,
blood samples for glycemia and lipid profile were identified. In addition, 6-minute walk,
stress test for maximum heart rate (HRM), anthropometry, quality of life, fatigue,
sarcopenia, depression, anxiety, clinical and hemodynamic parameters. All tests were done
before and after 36 training sessions of 70 minutes, 3 times a week.
Status | Completed |
Enrollment | 1573 |
Est. completion date | February 2019 |
Est. primary completion date | January 2017 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years to 80 Years |
Eligibility |
Inclusion Criteria: - Participants with cancer stadium II - To sign an informed consent endorsed by the ethics and research committee of the institution. - Participants with ejection fraction greater than 35% - Participants do not have any inconvenience when doing the questionnaires, tests and measures that the investigation demands, - Participants than will can to go 3 times a week for Cardiovascular rehabilitation. Exclusion Criteria: - Participants who had severe pain in the lower or upper limbs. - Unstable angina. - Heart rate >120 bpm (beats per minute) at rest. - Systolic blood pressure >190 mmHg. - Diastolic blood pressure >120 mmHg. - Participants who had a positive contraindication make exercise were not admitted in the study. - Participants to show hemodynamic instability without improving during any test or during the intervention process. |
Country | Name | City | State |
---|---|---|---|
n/a |
Lead Sponsor | Collaborator |
---|---|
University Tolteca |
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Changes in ejection fraction after 36 training sessions (%) | it is the most important measure of cardiac functioning. This value, expressed as a percentage, measures the decrease in the volume of the left ventricle of the heart in systole, with respect to the diastole. The normal values are higher than 45%. | After 3 month of training (36 training sessions) | |
Primary | Changes of the maximum heart rate in a effort test after 36 training sessions | It is the maximum capacity that the heart has to contract and we determine it by means of an effort test. The Maximum heart rate can be determined by formula or in a effort test (In the present investigation) which consists in mounting the participant in an endless band with an inclination and speed determined according to the protocol for said test. The test is stopped when the participant. indicates that it can not be more or there are electrocardiographic alterations that indicate that it is the participant's maximum. | After 3 month of training (36 training sessions) | |
Primary | Changes in the Body weight after 36 training sessions (Kg) | How much body weight (kg) pre and post intervention | After 3 month of training (36 training sessions) | |
Primary | Changes in the Body Mass Index after 36 training sessions (%) | it is a mathematical reason that associates the mass and the size of an individual. it is also known as the Quetelet index. This result is determined by the formula of weight/square size. | After 3 month of training (36 training sessions) | |
Primary | Changes in the Abdominal circumference after 36 training sessions (cm) | It is the measurement of the distance around the abdomen at a specific point. Abdominal circumference is used to diagnose and monitor abdominal obesity. The values are in centimeters and according to the population to be studied, the measurements must be less than 90cm for men and 80cm for women. | After 3 month of training (36 training sessions) | |
Primary | Changes in the Fat percentage after 36 training sessions (%) | Percentage of body fat is considered a measure to determine the level of body fat and a high percentage is a risk factor that triggers multiple chronic diseases. This measure can be determined in many ways but in our study it was used by means of bioimpedance. The normal values for men and women depend on the age of the patients and the manufacturer of the scale. | After 3 month of training (36 training sessions) | |
Primary | Changes in the Muscle percentage after after 36 training sessions (%) | Muscle percentage is considered a measure to determine the level of muscle in the body and a low percentage is a risk factor that indicates sarcopenia and is associated with a decrease in quality of life. This measure can be determined in many ways but in our study it was used by means of bioimpedance. The normal values for men and women depend on the age of the patients and the manufacturer of the scale. | After 3 month of training (36 training sessions) | |
Primary | Changes in the levels of Depression and Anxiety after 36 training sessions | Psychological alteration that can be determined by the "Hospital Anxiety and Depression Scale". This scale consists of a series of questions for depression and others for anxiety. The final grade is in the range of 1 to 10 and for the diagnosis of depression or anxiety the result must be greater than or equal to 8. | After 3 month of training (36 training sessions) | |
Primary | Changes in the levels of force after 36 training sessions | Strength is the physical ability to perform a job or a movement. It can be assessed with 1 maximum repetition and the maximum weight the participant manages to lift will be the reference value for his prescription. In addition, muscle strength can be assessed by dynamometry and indicates low, normal or high muscle strength. Their values depend on the age and sex of the participant. | After 3 month of training (36 training sessions) | |
Primary | Changes in the levels of Sarcopenia after 36 training sessions | Sarcopenia is the degenerative loss of muscle mass and strength as you get older. It is of high prevalence in patients with cancer. Sarcopenia is assessed according to the European Consensus on Sarcopenia (2010) who presented a diagnostic algorithm based on three criteria. Exploration of gait, muscle strength and muscle mass. For the first criterion, we use the Short Physical Performance Battery (SPPB). For the second criterion, the muscular strength, the dynamometry test is used (See force section). And in a final criterion, the muscle mass was assessed using the body mass index and the circumference of the calf, taking as a cut-off point the 31 cm. |
After 3 month of training (36 training sessions) | |
Primary | Changes in the levels of Fatigue after 36 training sessions | Fatigue was assessed using the FACT-Fatigue Scale Scale (Fatigue Scale of the Functional Evaluation of Cancer Therapy), which is an inventory of 13 items that assesses the severity of cancer-associated fatigue (FAC) in the last week. with a scale of 0 to 4 and that with higher scores reflect a lower FAC. | After 3 month of training (36 training sessions) | |
Primary | Changes in the levels of Quality of life after 36 training sessions | For the quality of life, it is necessary to use the questionnaire called EORTC QLQ-C30 (Version 3), which has 30 questions, where each question will go with a score of 1 to 4 and the higher the final result the better the quality of life. participant's life | After 3 month of training (36 training sessions) | |
Primary | Changes in the levels of Total cholesterol after 36 training sessions (mg/dl) | It is part of the measures to determine the lipid profile of a person and serves to determine different types of dyslipidemia. This item is obtained by means of a blood sample analyzed in a clinical laboratory and the result obtained by a professional for this purpose. Values above 200 mg/dl are indicative of a lipid alteration. | After 3 month of training (36 training sessions) | |
Primary | Changes in the levels of Triglycerides after 36 training sessions (mg/dl) | It is part of the measures to determine the lipid profile of a person and serves to determine different types of dyslipidemia. This item is obtained by means of a blood sample analyzed in a clinical laboratory and the result obtained by a professional for this purpose. Values above 150 mg/dl are indicative of a lipid alteration. | After 3 month of training (36 training sessions) | |
Primary | Changes in the levels of LDL after 36 training sessions (mg/dl) | It is part of the measures to determine the lipid profile of a person and serves to determine different types of dyslipidemia. This item is obtained by means of a blood sample analyzed in a clinical laboratory and the result obtained by a professional for this purpose. Values above 100 mg/dl are indicative of a lipid alteration. | After 3 month of training (36 training sessions) | |
Primary | Changes in the levels of HDL after 36 training sessions (mg/dl) | It is part of the measures to determine the lipid profile of a person and serves to determine different types of dyslipidemia.This item is obtained by means of a blood sample analyzed in a clinical laboratory and the result obtained by a professional for this purpose. Values lower than 40 mg/dl are indicative of a lipid alteration. | After 3 month of training (36 training sessions) | |
Primary | Changes in the levels of Glucose after 36 training sessions (mg/dl) | It is used to determine blood glucose levels and its high values are indicative for diabetes mellitus. This item is obtained by means of a blood sample analyzed in a clinical laboratory and the result obtained by a professional for this purpose. Values lower than 126 mg/dl are indicative of diabetes mellitus. | After 3 month of training (36 training sessions) | |
Secondary | Changes in the Estimated maximum oxygen volume after 36 training sessions (ml/kg/min) | It is the maximum amount of oxygen that the body can absorb, transport and consume in a given time, is the blood that our body can transport and metabolize. To determine the Vo2 values, the 6-minute walking test is used and to determine the result of the test, formulas are used according to the meters traveled, age, sex, height and weight of the participant. The larger the meters traveled, the greater the vo2. | After 3 month of training (36 training sessions) | |
Secondary | Changes in the unit of measurement of the metabolic index (METs) after 36 training sessions (ml/kg/min) | It is the unit of measurement of the metabolic index (amount of energy consumed by an individual in a resting situation). To determine the METs values, the 6-minute walking test is used and to determine the result of the test, formulas are used according to the meters traveled, age, sex, height and weight of the participant. The larger the meters traveled, the greater the METs. | After 3 month of training (36 training sessions) | |
Secondary | Changes in the Distance traveled after 36 training sessions (m) | Distance traveled in this of 6 minute walk test. The larger the meters traveled, this will indicate better Vo2, METs and aerobic and physical capacity in the participant. | After 3 month of training (36 training sessions) | |
Secondary | Changes in the Dyspnoea after 36 training sessions | Dyspnea is a respiratory difficulty that usually translates into shortness of breath. Dyspnea can be determined using the original Borg scale (Score from 0 to 20) or modified (Score from 0 to 10), in which the higher the number indicated by the participant, the higher the degree of dyspnea. | After 3 month of training (36 training sessions) |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05346796 -
Survivorship Plan HEalth REcord (SPHERE) Implementation Trial
|
N/A | |
Recruiting |
NCT05094804 -
A Study of OR2805, a Monoclonal Antibody Targeting CD163, Alone and in Combination With Anticancer Agents
|
Phase 1/Phase 2 | |
Completed |
NCT04867850 -
Effect of Behavioral Nudges on Serious Illness Conversation Documentation
|
N/A | |
Enrolling by invitation |
NCT04086251 -
Remote Electronic Patient Monitoring in Oncology Patients
|
N/A | |
Completed |
NCT01285037 -
A Study of LY2801653 in Advanced Cancer
|
Phase 1 | |
Completed |
NCT00680992 -
Study of Denosumab in Subjects With Giant Cell Tumor of Bone
|
Phase 2 | |
Completed |
NCT00062842 -
Study of Irinotecan on a Weekly Schedule in Children
|
Phase 1 | |
Active, not recruiting |
NCT04548063 -
Consent Forms in Cancer Research: Examining the Effect of Length on Readability
|
N/A | |
Completed |
NCT04337203 -
Shared Healthcare Actions and Reflections Electronic Systems in Survivorship
|
N/A | |
Recruiting |
NCT04349293 -
Ex-vivo Evaluation of the Reactivity of the Immune Infiltrate of Cancers to Treatments With Monoclonal Antibodies Targeting the Immunomodulatory Pathways
|
N/A | |
Terminated |
NCT02866851 -
Feasibility Study of Monitoring by Web-application on Cytopenia Related to Chemotherapy
|
N/A | |
Active, not recruiting |
NCT05304988 -
Development and Validation of the EFT for Adolescents With Cancer
|
||
Completed |
NCT04448041 -
CRANE Feasibility Study: Nutritional Intervention for Patients Undergoing Cancer Surgery in Low- and Middle-Income Countries
|
||
Completed |
NCT00340522 -
Childhood Cancer and Plexiform Neurofibroma Tissue Microarray for Molecular Target Screening and Clinical Drug Development
|
||
Recruiting |
NCT04843891 -
Evaluation of PET Probe [64]Cu-Macrin in Cardiovascular Disease, Cancer and Sarcoidosis.
|
Phase 1 | |
Active, not recruiting |
NCT03844048 -
An Extension Study of Venetoclax for Subjects Who Have Completed a Prior Venetoclax Clinical Trial
|
Phase 3 | |
Completed |
NCT03109041 -
Initial Feasibility Study to Treat Resectable Pancreatic Cancer With a Planar LDR Source
|
Phase 1 | |
Completed |
NCT03167372 -
Pilot Comparison of N-of-1 Trials of Light Therapy
|
N/A | |
Terminated |
NCT01441115 -
ECI301 and Radiation for Advanced or Metastatic Cancer
|
Phase 1 | |
Recruiting |
NCT06206785 -
Resting Energy Expenditure in Palliative Cancer Patients
|